366789-02-8 | 5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
5mg	98%	in stock	$8.00	$6.00
10mg	98%	in stock	$10.00	$7.00
50mg	98%	in stock	$12.00	$9.00
1g	98%	in stock	$16.00	$11.00
5g	98%	in stock	$65.00	$46.00
10g	98%	in stock	$122.00	$86.00
25g	98%	in stock	$235.00	$165.00
100g	98%	in stock	$713.00	$499.00

Description

• Catalog Number: AB46989
• Chemical Name: 5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
• CAS Number: 366789-02-8
• Molecular Formula: C19H18ClN3O5S
• Molecular Weight: 435.8813
• MDL Number: MFCD11974010
• SMILES: O=C1O[C@H](CN1c1ccc(cc1)N1CCOCC1=O)CNC(=O)c1ccc(s1)Cl

Computed Properties

• Complexity: 645
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 2.5

Literature

• Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve.

  International journal of cardiology 20150601

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Overview of the new oral anticoagulants: opportunities and challenges.

  Arteriosclerosis, thrombosis, and vascular biology 20150501

• The role of factor Xa inhibitors in venous thromboembolism treatment.

  Vascular health and risk management 20150101

• Pharmacology of the new target-specific oral anticoagulants.

  Journal of thrombosis and thrombolysis 20130801

• Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.

  European journal of medicinal chemistry 20130601

• A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

  Nature medicine 20130401

• Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.

  Thrombosis research 20130301

• New anticoagulants for treatment of venous thromboembolism.

  European journal of internal medicine 20121201

• Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.

  Thrombosis research 20121101

• Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.

  Thrombosis research 20121101

• Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.

  Journal of thrombosis and thrombolysis 20121101

• The in vitro anticoagulant effect of rivaroxaban in children.

  Thrombosis research 20121101

• Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

  British journal of haematology 20121101

• Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

  Thrombosis and haemostasis 20121101

• Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

  Thrombosis and haemostasis 20121101

• Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.

  Thrombosis and haemostasis 20121101

• The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.

  The Journal of bone and joint surgery. British volume 20121101

• [New anticoagulants - direct factor Xa-inhibitors].

  Therapeutische Umschau. Revue therapeutique 20121101

• [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].

  Therapeutische Umschau. Revue therapeutique 20121101

• [Clinical pharmacological aspects of new oral anticoagulants].

  Therapeutische Umschau. Revue therapeutique 20121101

• How I treat anticoagulated patients undergoing an elective procedure or surgery.

  Blood 20121011

• Oral thromboprophylaxis in pelvic trauma: a standardized protocol.

  The Journal of emergency medicine 20121001

• For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding.

  Evidence-based medicine 20121001

• Effects on platelet function of a direct acting antagonist of coagulation factor Xa.

  Journal of thrombosis and thrombolysis 20121001

• Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

• Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

  PharmacoEconomics 20121001

• Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.

  QJM : monthly journal of the Association of Physicians 20121001

• Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20121001

• Anticoagulants in atrial fibrillation patients with chronic kidney disease.

  Nature reviews. Nephrology 20121001

• Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.

  European journal of haematology 20121001

• Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.

  Journal of thrombosis and haemostasis : JTH 20121001

• Atrial fibrillation in long term care.

  Journal of the American Medical Directors Association 20121001

• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

  Thrombosis and haemostasis 20121001

• New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

• New anticoagulants: A concise review.

  The journal of trauma and acute care surgery 20121001

• [Prophylaxis of thromboembolic events following hip and knee replacement: dabigatran, rivaroxaban or apixaban in comparison to enoxaparin].

  Der Unfallchirurg 20121001

• What did we learn from new oral anticoagulant treatment?

  Thrombosis research 20121001

• Antithrombotic treatment of atrial fibrillation: new insights.

  Thrombosis research 20121001

• Do new oral anticoagulants require laboratory monitoring? The clinician point of view.

  Thrombosis research 20121001

• Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.

  Clinical chemistry and laboratory medicine 20121001

• The new oral anticoagulants and the future of haemostasis laboratory testing.

  Biochemia medica 20121001

• Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.

  Cardiovascular journal of Africa 20121001

• Oral direct factor Xa inhibitors.

  Circulation research 20120928

• ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF.

  Annals of internal medicine 20120918

• Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.

  The American journal of cardiology 20120915

• New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

  Drugs 20120910

• Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.

  Journal of cardiovascular pharmacology and therapeutics 20120901

• Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120901

• Antithrombotic options for atrial fibrillation in 2012.

  Cardiovascular & hematological disorders drug targets 20120901

• Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients.

  Orthopaedics & traumatology, surgery & research : OTSR 20120901

• Treatment of venous thromboembolism with dabigatran.

  Current opinion in pulmonary medicine 20120901

• Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

  Coronary artery disease 20120901

• The management of antithrombotic medication in skin surgery.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20120901

• An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

  Thrombosis and haemostasis 20120901

• [The ROCKET AF study].

  Giornale italiano di cardiologia (2006) 20120901

• Letter to the Editor regarding 'effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma'.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20120901

• Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120901

• Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.

  Circulation. Cardiovascular quality and outcomes 20120901

• The novel oral anticoagulants: an update for the interventional radiologist.

  AJR. American journal of roentgenology 20120901

• [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].

  Therapeutische Umschau. Revue therapeutique 20120901

• Drug interactions with rivaroxaban following total joint replacement surgery.

  The Annals of pharmacotherapy 20120901

• The promise of novel direct oral anticoagulants.

  Best practice & research. Clinical haematology 20120901

• Advances in the management of venous thromboembolism.

  Best practice & research. Clinical haematology 20120901

• Apixaban. After hip or knee replacement: LMWH remains the standard treatment.

  Prescrire international 20120901

• Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

  Journal of the American College of Cardiology 20120821

• Danger ahead: watch out for indirect comparisons!

  Journal of the American College of Cardiology 20120821

• ACP Journal Club: review: factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.

  Annals of internal medicine 20120821

• ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PE.

  Annals of internal medicine 20120821

• Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.

  Thrombosis research 20120801

• A new era of antithrombotic therapy in patients with atrial fibrillation.

  The American journal of the medical sciences 20120801

• Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

  Thrombosis research 20120801

• Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

  The American journal of cardiology 20120801

• Novel anticoagulants for non-valvular atrial fibrillation.

  Heart, lung & circulation 20120801

• Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?

  Current clinical pharmacology 20120801

• Oral IIa and Xa inhibitors for prevention of stroke in atrial fibrillation: clinical studies and regulatory considerations.

  Current clinical pharmacology 20120801

• Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants.

  Current clinical pharmacology 20120801

• Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.

  Journal of cardiothoracic and vascular anesthesia 20120801

• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.

  Thrombosis and haemostasis 20120801

• Anticoagulation-related intracranial hemorrhages.

  Current atherosclerosis reports 20120801

• Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.

  Thrombosis and haemostasis 20120801

• Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

  International angiology : a journal of the International Union of Angiology 20120801

• Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA?

  The Lancet. Neurology 20120801

• [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].

  Zeitschrift fur Gerontologie und Geriatrie 20120801

• Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.

  Minerva cardioangiologica 20120801

• Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.

  Expert review of cardiovascular therapy 20120801

• Periprocedural anticoagulant management.

  Hospital practice (1995) 20120801

• The new oral anticoagulants: a challenge for hospital formularies.

  Hospital practice (1995) 20120801

• New oral anticoagulants for atrial fibrillation.

  Circulation 20120703

• Renal profiles of anticoagulants.

  Journal of clinical pharmacology 20120701

• Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.

  British journal of clinical pharmacology 20120701

• Pharmacologic and nonpharmacologic therapies for stroke prevention in nonvalvular atrial fibrillation.

  Pacing and clinical electrophysiology : PACE 20120701

• Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.

  Thrombosis and haemostasis 20120701

• Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.

  Expert opinion on drug metabolism & toxicology 20120701

• New drugs 2012, part 2.

  Nursing 20120701

• Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

  Circulation. Cardiovascular quality and outcomes 20120701

• Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.

  Future cardiology 20120701

• Pneumococcal vaccines; use of rivaroxaban for DVT and PE.

  JAAPA : official journal of the American Academy of Physician Assistants 20120701

• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.

  Journal of thrombosis and haemostasis : JTH 20120701

• Oral rivaroxaban for pulmonary embolism.

  The New England journal of medicine 20120628

• Oral rivaroxaban for pulmonary embolism.

  The New England journal of medicine 20120628

• Oral rivaroxaban for pulmonary embolism.

  The New England journal of medicine 20120628

• Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

  Drugs 20120618

• New oral anticoagulants for venous thromboembolism: focus on factor Xa and thrombin inhibitors.

  Current drug discovery technologies 20120601

• Discovery of anticoagulant drugs: a historical perspective.

  Current drug discovery technologies 20120601

• Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban).

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20120601

• The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

  Thrombosis and haemostasis 20120601

• Novel oral anticoagulants after acute coronary syndromes.

  Cardiovascular drugs and therapy 20120601

• Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.

  Thrombosis and haemostasis 20120601

• New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

  Journal of internal medicine 20120601

• Novel antithrombotic agents for atrial fibrillation.

  Pharmacology & therapeutics 20120601

• Long-term benefits of preventing venous thromboembolic events.

  Current medical research and opinion 20120601

• [New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].

  Herz 20120601

• [Pharmacology of the new oral anticoagulants].

  Herz 20120601

• [Role of the new oral anticoagulants in comparison to vitamin K antagonists in practice].

  Herz 20120601

• [Anticoagulation. Modern concepts].

  Herz 20120601

• Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.

  Critical pathways in cardiology 20120601

• A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation.

  Critical pathways in cardiology 20120601

• The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.

  Expert opinion on therapeutic patents 20120601

• Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

  Advances in therapy 20120601

• Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.

  Orthopedics 20120601

• Efficacy of extramedullary femoral component alignment guide system for blood saving after total knee arthroplasty.

  Knee surgery & related research 20120601

• Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved drugs.

  Discovery medicine 20120601

• Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery.

  The Nurse practitioner 20120511

• Anticoagulant therapy for patients with ischaemic stroke.

  Nature reviews. Neurology 20120508

• Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.

  Nature reviews. Cardiology 20120508

• Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

  Drugs 20120507

• Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

  European journal of clinical pharmacology 20120501

• Tissue factor-driven thrombin generation and inflammation in atherosclerosis.

  Thrombosis research 20120501

• Reversal of antithrombotic agents.

  American journal of hematology 20120501

• Advances in laboratory testing for thrombophilia.

  American journal of hematology 20120501

• Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

  American journal of hematology 20120501

• Implementing the new oral anticoagulants into the hospital formulary.

  American journal of hematology 20120501

• Prevention of venous thromboembolism in total knee and hip replacement.

  Circulation 20120501

• Novel oral anticoagulants--key messages for the angiologist.

  VASA. Zeitschrift fur Gefasskrankheiten 20120501

• New oral anticoagulants: will they replace warfarin?

  Oral surgery, oral medicine, oral pathology and oral radiology 20120501

• Oral anticoagulants for atrial fibrillation: Which one to choose?

  Advance for NPs & PAs 20120501

• Newer oral anticoagulant agents: a new era in medicine.

  Current cardiology reviews 20120501

• Letter by Bernstein et al regarding article, 'reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

  Circulation 20120424

• Letter by Marlu et al regarding article, 'reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects'.

  Circulation 20120424

• [Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].

  MMW Fortschritte der Medizin 20120419

• New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

  Journal of the American College of Cardiology 20120417

• Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.

  Circulation 20120410

• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  The New England journal of medicine 20120405

• Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.

  Thrombosis research 20120401

• Novel anticoagulants for atrial fibrillation: a critical appraisal.

  Angiology 20120401

• Should deep venous thrombosis prophylaxis be used in fast-track hip and knee replacement?

  Acta orthopaedica 20120401

• Rivaroxaban and recurrent stroke prevention in AF.

  The Lancet. Neurology 20120401

• Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

  The Lancet. Neurology 20120401

• New oral anticoagulants for atrial fibrillation: a review of clinical trials.

  Clinical therapeutics 20120401

• Rivaroxaban: a new oral anticoagulant.

  Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 20120401

• Preventing venous thromboembolic events after total hip arthroplasty: new developments in clinical practice.

  Hospital practice (1995) 20120401

• Thromboprophylaxis in surgical and medical patients.

  Seminars in respiratory and critical care medicine 20120401

• Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.

  Oral surgery, oral medicine, oral pathology and oral radiology 20120401

• How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

  Blood 20120329

• [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].

  MMW Fortschritte der Medizin 20120322

• Rivaroxaban vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.

  American family physician 20120315

• Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

  Thrombosis and haemostasis 20120301

• Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.

  Thrombosis research 20120301

• Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.

  Biopharmaceutics & drug disposition 20120301

• What's the 'go to' anticoagulant for stroke prevention in atrial fibrillation?

  Thrombosis and haemostasis 20120301

• New directions in anticoagulation.

  The American journal of medicine 20120301

• A new generation of oral direct anticoagulants.

  Arteriosclerosis, thrombosis, and vascular biology 20120301

• Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20120301

• Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.

  Expert review of cardiovascular therapy 20120301

• Coagulopathies and thrombosis: usual and unusual causes and associations, part VI.

  Seminars in thrombosis and hemostasis 20120301

• Determination of rivaroxaban in human plasma samples.

  Seminars in thrombosis and hemostasis 20120301

• The efficacy and safety of postoperative autologous transfusion of filtered shed blood and anticoagulant prophylaxis in total knee arthroplasty patients.

  Knee surgery & related research 20120301

• Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.

  Nature reviews. Cardiology 20120227

• Oral factor Xa inhibitors for the long-term management of ACS.

  Nature reviews. Cardiology 20120221

• Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

  Blood 20120202

• Anticoagulant management in the cardiovascular setting.

  Fundamental & clinical pharmacology 20120201

• Pharmacodynamic and pharmacokinetic basics of rivaroxaban.

  Fundamental & clinical pharmacology 20120201

• Rivaroxaban for the prevention and treatment of venous thromboembolism.

  Fundamental & clinical pharmacology 20120201

• New anticoagulants for the prevention of stroke in atrial fibrillation.

  Fundamental & clinical pharmacology 20120201

• Lack of an antagonist to reverse the action of dabigatran.

  QJM : monthly journal of the Association of Physicians 20120201

• Management of coagulation: an Australian perspective.

  Current opinion in anaesthesiology 20120201

• Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.

  Thrombosis and haemostasis 20120201

• Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

  PharmacoEconomics 20120201

• Cost-effectiveness of pharmacologic and invasive therapies for stroke prophylaxis in atrial fibrillation.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20120201

• The year in Cardiothoracic and Vascular Anesthesia: selected highlights from 2011.

  Journal of cardiothoracic and vascular anesthesia 20120201

• The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?

  International journal of stroke : official journal of the International Stroke Society 20120201

• Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.

  Expert review of hematology 20120201

• Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120201

• Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

  Expert review of neurotherapeutics 20120201

• Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis.

  Seminars in thrombosis and hemostasis 20120201

• Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].

  MMW Fortschritte der Medizin 20120119

• Rivaroxaban reduced stroke and systemic embolism compared with warfarin in nonvalvular AF.

  Annals of internal medicine 20120117

• Rivaroxaban in patients with a recent acute coronary syndrome.

  The New England journal of medicine 20120105

• A new era in secondary prevention after acute coronary syndrome.

  The New England journal of medicine 20120105

• New anticoagulants - promising and failed developments.

  British journal of pharmacology 20120101

• Novel oral anticoagulants: new challenges for anesthesiologists in bleeding patients.

  Anesthesiology 20120101

• Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.

  Thrombosis research 20120101

• Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

  Anesthesiology 20120101

• Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

  Journal of neurology 20120101

• [Anticoagulation in atrial fibrillation: a new era has begun].

  Hamostaseologie 20120101

• [Anticoagulation for atrial fibrillation : the future has begun].

  Der Internist 20120101

• Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens.

  The Journal of bone and joint surgery. British volume 20120101

• [Apixaban: pharmacology and action profile].

  Deutsche medizinische Wochenschrift (1946) 20120101

• New frontiers for stroke prevention in atrial fibrillation.

  Cerebrovascular diseases (Basel, Switzerland) 20120101

• [Summary of the article: Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365: 1557-1559].

  Kardiologia polska 20120101

• ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?

  Cardiology journal 20120101

• New antiplatelet and anticoagulant drugs.

  General dentistry 20120101

• Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.

  Postgraduate medicine 20120101

• New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

  Vascular health and risk management 20120101

• I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?

  DukeMedicine healthnews 20120101

• A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?

  Polskie Archiwum Medycyny Wewnetrznej 20120101

• Newer anticoagulants in cardiovascular disease: a systematic review of the literature.

  Cardiology in review 20120101

• Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.

  Connecticut medicine 20120101

• Improving prevention and treatment of venous thromboembolism: clinical trial results.

  Journal of medical economics 20120101

• Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120101

• The WATCHMAN left atrial appendage closure device for atrial fibrillation.

  Journal of visualized experiments : JoVE 20120101

• Stroke Prevention in Atrial Fibrillation: Where are We Now?

  Clinical Medicine Insights. Cardiology 20120101

• Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.

  The Canadian journal of cardiology 20120101

• [Update on current care guidelines: atrial fibrillation].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

  Journal of medical economics 20120101

• The Anticoagulation of Calf Thrombosis (ACT) project: study protocol for a randomized controlled trial.

  Trials 20120101

• Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.

  Journal of medical economics 20120101

• Current status of new anticoagulants in the management of venous thromboembolism.

  Advances in hematology 20120101

• Costs and clinical consequences of suboptimal atrial fibrillation management.

  ClinicoEconomics and outcomes research : CEOR 20120101

• The Interface between Inflammation and Coagulation in Cardiovascular Disease.

  International journal of inflammation 20120101

• Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery.

  Therapeutics and clinical risk management 20120101

• Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.

  Reviews in cardiovascular medicine 20120101

• The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients.

  ClinicoEconomics and outcomes research : CEOR 20120101

• Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants.

  Journal of blood medicine 20120101

• Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease.

  Thrombosis 20120101

• Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report.

  Journal of medical case reports 20120101

• [New antithrombotic drugs].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Advances in the diagnosis and treatment of acute pulmonary embolism.

  F1000 medicine reports 20120101

• Reviewing the medical literature: five notable articles in general internal medicine from 2010 and 2011.

  Open medicine : a peer-reviewed, independent, open-access journal 20120101

• Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians.

  PloS one 20120101

• Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging 'real-world' questions.

  Thrombosis 20120101

• Newer anticoagulants for the prevention of venous thromboembolism.

  The National medical journal of India 20120101

• Emerging anticoagulants.

  Current medicinal chemistry 20120101

• Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

  BMJ (Clinical research ed.) 20120101

• Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.

  Vascular health and risk management 20120101

• Health technology assessment and its role in the future development of the Indian healthcare sector.

  Perspectives in clinical research 20120101

• [Rivaroxaban in the prevention and treatment of thromboembolic disorders].

  Hamostaseologie 20120101

• [New anticoagulants: dabigatran, rivaroxaban and apixaban].

  Gaceta medica de Mexico 20120101

• An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.

  Core evidence 20120101

• Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

  Current medicinal chemistry 20120101

• Perioperative stroke risk in nonvascular surgery.

  Cerebrovascular diseases (Basel, Switzerland) 20120101

• Vitamin K antagonists. Ready to be replaced?

  Hamostaseologie 20120101

• Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis.

  Orthopedic nursing 20120101

• Rivaroxaban in atrial fibrillation.

  Vascular health and risk management 20120101

• Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective.

  Polskie Archiwum Medycyny Wewnetrznej 20120101

• Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban.

  Thrombosis 20120101

• [New oral anticoagulants for atrial fibrillation: a neurologist's view].

  Nederlands tijdschrift voor geneeskunde 20120101

• Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?

  Thrombosis 20120101

• Thromboembolic prophylaxis in total joint arthroplasty.

  Thrombosis 20120101

• Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials.

  BMJ open 20120101

• [Therapeutic approach to the bleeding in association with 'old' and 'new' anticoagulants].

  Vnitrni lekarstvi 20120101

• [Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis].

  Hamostaseologie 20120101

• Left atrial appendage exclusion for stroke prevention in atrial fibrillation.

  Cardiology research and practice 20120101

• Rationalizing tight ligand binding through cooperative interaction networks.

  Journal of chemical information and modeling 20111227

• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  The New England journal of medicine 20111215

• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  The New England journal of medicine 20111215

• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  The New England journal of medicine 20111215

• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  The New England journal of medicine 20111215

• Rivaroxaban (Xarelto) for acute coronary syndrome.

  The Medical letter on drugs and therapeutics 20111212

• Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.

  Journal of medicinal chemistry 20111208

• Antiplatelet agents and anticoagulants for hypertension.

  The Cochrane database of systematic reviews 20111207

• Drugs in traffic: the road to approval.

  Nature medicine 20111206

• Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.

  Journal of cardiovascular pharmacology 20111201

• New anticoagulants: moving on from scientific results to clinical implementation.

  Annals of medicine 20111201

• Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111201

• Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111201

• Intraarticular vs. extraarticular ropivacaine infusion following high-dose local infiltration analgesia after total knee arthroplasty: a randomized double-blind study.

  Acta orthopaedica 20111201

• [Stabilization of inter- and subtrochanteric femoral fractures with the PFNΑ®].

  Operative Orthopadie und Traumatologie 20111201

• Laboratory testing of anticoagulants: the present and the future.

  Pathology 20111201

• [Thrombosis prophylaxis in surgery. What is the evidence?].

  Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 20111201

• Antithrombotic therapy in nonvalvular atrial fibrillation: a narrative review.

  Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 20111201

• Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.

  Pharmacotherapy 20111201

• [Pharmacologic heterogeneity of new anticoagulants].

  Journal des maladies vasculaires 20111201

• [New treatments for venous thromboembolic disease].

  Journal des maladies vasculaires 20111201

• [Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects].

  MMW Fortschritte der Medizin 20111201

• [Rivaroxaban is not inferior compared with warfarin as an anticoagulant in patients with non-valvular atrial fibrillation].

  Praxis 20111130

• Acute coronary syndromes: Rivaroxaban reduces serious CV events without increasing fatal bleeding in patients with a recent ACS.

  Nature reviews. Cardiology 20111129

• FDA advisory decision highlights some problems inherent in pragmatic trials.

  JAMA 20111102

• Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies.

  Current vascular pharmacology 20111101

• Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.

  Journal of thrombosis and thrombolysis 20111101

• Rationale and current perspective for early rhythm control therapy in atrial fibrillation.

  Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 20111101

• Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.

  Thrombosis and haemostasis 20111101

• [New anticoagulants. Characteristics, monitoring and management of bleeding].

  Medizinische Klinik, Intensivmedizin und Notfallmedizin 20111101

• A study of thromboprophylactic practices of Scottish orthopaedic surgeons in patients undergoing total hip replacements. Should practice change with new guidelines?

  Scottish medical journal 20111101

• [Effect of rivaroxaban on risk of bleeding after total knee arthroplasty].

  Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 20111101

• [Current status and future of anti-Xa inhibitors].

  Rinsho shinkeigaku = Clinical neurology 20111101

• [New anticoagulants].

  La Revue du praticien 20111101

• Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

  The New England journal of medicine 20111027

• Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

  Circulation 20111004

• Reversal of new oral anticoagulants.

  Circulation 20111004

• Oral rivaroxaban for acute DVT, or long term for VTE, is as effective as enoxaparin followed by a vitamin K antagonist for preventing recurrence, with no increase in bleeding complications.

  Evidence-based medicine 20111001

• Inhibitors of propagation of coagulation: factors V and X.

  British journal of clinical pharmacology 20111001

• A role for coagulation factor Xa in experimental pulmonary arterial hypertension.

  Cardiovascular research 20111001

• New anticoagulants: how to deal with treatment failure and bleeding complications.

  British journal of clinical pharmacology 20111001

• Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty.

  Canadian journal of surgery. Journal canadien de chirurgie 20111001

• Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20111001

• Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.

  Journal of thrombosis and thrombolysis 20111001

• Anticoagulating obese patients in the modern era.

  British journal of haematology 20111001

• Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.

  European heart journal 20111001

• RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.

  European heart journal 20111001

• Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

  Clinical pharmacokinetics 20111001

• New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.

  Pharmacotherapy 20111001

• Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

  Orthopedics 20111001

• Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.

  Expert review of pharmacoeconomics & outcomes research 20111001

• Dutch guideline on total hip prosthesis.

  Acta orthopaedica 20111001

• The new oral anticoagulants.

  Clinical medicine (London, England) 20111001

• Xarelto: a new drug for new joints. Hip and knee recipients can avoid postsurgical clots without undergoing painful injections.

  The Johns Hopkins medical letter health after 50 20111001

• [New antithrombotic drugs for the treatment of venous thromboembolism].

  Revue des maladies respiratoires 20111001

• [Atrial fibrillation: what the GP needs to know].

  MMW Fortschritte der Medizin 20110922

• [Modern risk assessment and stroke prevention in atrial fibrillation].

  Praxis 20110921

• A new era for anticoagulation in atrial fibrillation.

  The New England journal of medicine 20110915

• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  The New England journal of medicine 20110908

• New options in anticoagulation for atrial fibrillation.

  The New England journal of medicine 20110908

• Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.

  Expert opinion on drug safety 20110901

• Emerging options in the treatment of deep vein thrombosis and pulmonary embolism.

  Blood reviews 20110901

• Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.

  Journal of thrombosis and haemostasis : JTH 20110901

• Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells.

  Thrombosis and haemostasis 20110901

• Update on anti-coagulation in atrial fibrillation.

  QJM : monthly journal of the Association of Physicians 20110901

• [Thromboembolic prophylaxis 2011: is warfarin on the wane?].

  Giornale italiano di cardiologia (2006) 20110901

• Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.

  British journal of hospital medicine (London, England : 2005) 20110901

• Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.

  Seminars in vascular surgery 20110901

• Rivaroxaban (Xarelto)--a new oral anticoagulant.

  The Medical letter on drugs and therapeutics 20110822

• New antithrombotic drugs and European approval processes.

  Lancet (London, England) 20110820

• Oral direct factor Xa inhibitor gets FDA's OK.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110815

• Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents.

  Journal of medicinal chemistry 20110811

• [The new Anticoagulants - Relevant Facts for the GP].

  Praxis 20110810

• [Rivaroxaban as therapy of deep venous thrombosis equally as effective as current anticoagulation with heparin and vitamin K antagonist].

  Praxis 20110810

• ['Xa-tra-xa': opportunities and open questions about new anticoagulants].

  Praxis 20110810

• Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.

  European heart journal 20110801

• Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.

  Journal of thrombosis and haemostasis : JTH 20110801

• New anticoagulants for prevention of stroke in patients with atrial fibrillation.

  Journal of cardiovascular electrophysiology 20110801

• Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time.

  Journal of thrombosis and haemostasis : JTH 20110801

• Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

• New oral anticoagulants for venous thromboembolism (VTE) prophylaxis.

  The Medical journal of Malaysia 20110801

• Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

  American journal of therapeutics 20110701

• In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.

  The Journal of pharmacology and experimental therapeutics 20110701

• Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.

  Current opinion in cardiology 20110701

• Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.

  Thrombosis and haemostasis 20110701

• Response to 'Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban'.

  Journal of clinical pharmacology 20110701

• Practical aspects of the oral new anticoagulants.

  American journal of hematology 20110701

• Treatment of risk factors to prevent stroke.

  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 20110701

• Optimal duration of anticoagulation in patients with venous thromboembolism.

  The Indian journal of medical research 20110701

• Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

  Expert review of cardiovascular therapy 20110701

• [New anticoagulants in the prevention and treatment of venous thromboembolism].

  Orvosi hetilap 20110619

• The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.

  Thrombosis research 20110601

• Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding.

  Current treatment options in cardiovascular medicine 20110601

• Treating arrhythmias: an expert opinion.

  Expert opinion on pharmacotherapy 20110601

• A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.

  Thrombosis research 20110601

• Rivaroxaban in the contemporary treatment of acute coronary syndromes.

  Expert opinion on investigational drugs 20110601

• Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.

  Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing 20110601

• Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.

  International angiology : a journal of the International Union of Angiology 20110601

• Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.

  Expert review of pharmacoeconomics & outcomes research 20110601

• 4-(3-Fluoro-4-nitro-phen-yl)morpholin-3-one.

  Acta crystallographica. Section E, Structure reports online 20110601

• [Is the era from the end of warfarin?].

  Medizinische Monatsschrift fur Pharmazeuten 20110601

• ACP journal club. Rivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment.

  Annals of internal medicine 20110517

• Update on pharmacologic approaches to prevent thromboembolism in atrial fibrillation: are thrombin and factor Xa inhibitors the ultimate answer?

  Current vascular pharmacology 20110501

• Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?

  Reviews on recent clinical trials 20110501

• Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.

  Thrombosis research 20110501

• Laboratory assessment of new anticoagulants.

  Clinical chemistry and laboratory medicine 20110501

• Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor.

  Journal of thrombosis and thrombolysis 20110501

• Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.

  Journal of thrombosis and thrombolysis 20110501

• Risk-benefit ratio assessment for stroke prevention in intermediate risk atrial fibrillation patients: will TEE-based aspirin treatment fill the gap?

  Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 20110501

• Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.

  American heart journal 20110501

• [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

  Medecine sciences : M/S 20110501

• Advances in cardiology: clinical trial update.

  Future cardiology 20110501

• [The new anticoagulants].

  Harefuah 20110501

• [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].

  MMW Fortschritte der Medizin 20110414

• Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa.

  Blood 20110407

• A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

  Cancer chemotherapy and pharmacology 20110401

• The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.

  Pharmacology & therapeutics 20110401

• Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?

  Thrombosis and haemostasis 20110401

• What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

  Thrombosis and haemostasis 20110401

• New oral anticoagulants.

  Journal of thrombosis and thrombolysis 20110401

• Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

  Journal of thrombosis and thrombolysis 20110401

• Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.

  Expert opinion on investigational drugs 20110401

• Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.

  European journal of heart failure 20110401

• Preventing postsurgical venous thromboembolism: pharmacological approaches.

  Seminars in thrombosis and hemostasis 20110401

• Oral rivaroxaban for symptomatic venous thromboembolism.

  The New England journal of medicine 20110324

• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.

  Thrombosis and haemostasis 20110301

• Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery.

  Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20110301

• Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.

  Expert opinion on pharmacotherapy 20110301

• Old and new anticoagulant drugs: a minireview.

  Annals of medicine 20110301

• Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.

  Drugs & aging 20110301

• Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.

  Drug safety 20110301

• The discovery and development of rivaroxaban.

  Annals of the New York Academy of Sciences 20110301

• Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.

  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20110201

• Rivaroxaban and false positive lupus anticoagulant testing.

  Thrombosis and haemostasis 20110201

• New anticoagulant agents in acute coronary syndromes.

  Heart (British Cardiac Society) 20110201

• Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

  Journal of clinical pharmacy and therapeutics 20110201

• Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism.

  Phlebology 20110201

• [New oral anticoagulants in atrial fibrillation].

  Der Nervenarzt 20110201

• Association of warfarin use with valvular and vascular calcification: a review.

  Clinical cardiology 20110201

• Old and new anticoagulants.

  Hamostaseologie 20110201

• New anticoagulants: pharmacology and clinical studies.

  Wiener medizinische Wochenschrift (1946) 20110201

• Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.

  Wiener medizinische Wochenschrift (1946) 20110201

• New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.

  The American journal of managed care 20110201

• Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

  The American journal of managed care 20110201

• Characteristics of novel anticoagulants and potential economic implications.

  The American journal of managed care 20110201

• Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.

  The American journal of managed care 20110201

• Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives.

  The American journal of managed care 20110201

• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.

  BMJ (Clinical research ed.) 20110118

• New alternative to warfarin may help reduce stroke risk in patients with AF.

  JAMA 20110105

• The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.

  Journal of thrombosis and haemostasis : JTH 20110101

• Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.

  Journal of thrombosis and haemostasis : JTH 20110101

• Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.

  Analytical and bioanalytical chemistry 20110101

• Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.

  Current vascular pharmacology 20110101

• The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

  Nature reviews. Drug discovery 20110101

• Factor Xa and thrombin as targets for new oral anticoagulants.

  Thrombosis research 20110101

• Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.

  The Journal of bone and joint surgery. British volume 20110101

• Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

  Annual review of medicine 20110101

• New oral anticoagulants: should they replace heparins and warfarin?

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20110101

• An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

  Journal of medical economics 20110101

• Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement.

  Patient preference and adherence 20110101

• [Perioperative venous thromboembolism prophylaxis].

  La Revue du praticien 20110101

• Heparin-induced thrombocytopenia in the ICU: an overview.

  Critical care (London, England) 20110101

• The pathology and treatment of cardiac arrhythmias: focus on atrial fibrillation.

  Vascular health and risk management 20110101

• Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.

  PloS one 20110101

• New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.

  Instructional course lectures 20110101

• Left Atrial Appendage Closure in Atrial Fibrillation: A World without Anticoagulation?

  Cardiology research and practice 20110101

• Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare.

  Implementation science : IS 20110101

• [Drug prevention of pulmonary embolism in orthopedic practice: traditional and novel approaches].

  Kardiologiia 20110101

• Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial.

  BMJ (Clinical research ed.) 20110101

• Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.

  Mediators of inflammation 20110101

• Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective.

  Thrombosis journal 20110101

• Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.

  Vascular health and risk management 20110101

• Antithrombotic medication for cardioembolic stroke prevention.

  Stroke research and treatment 20110101

• Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic.

  BMC family practice 20110101

• Strategies for diagnosis and prevention of venous thromboembolism during pregnancy.

  Journal of pregnancy 20110101

• FDA approves rivaroxaban for prevention of deep-vein thrombosis in surgery.

  Cardiovascular journal of Africa 20110101

• Evaluation of marine brown algae and sponges from Brazil as anticoagulant and antiplatelet products.

  Marine drugs 20110101

• Anesthesia for joint replacement surgery: Issues with coexisting diseases.

  Journal of anaesthesiology, clinical pharmacology 20110101

• Tissue factor, blood coagulation, and beyond: an overview.

  International journal of inflammation 20110101

• Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.

  Advances in surgery 20110101

• [The new oral anticoagulants in surgery].

  Revista medica del Instituto Mexicano del Seguro Social 20110101

• European Society of Cardiology congress 2011.

  Cardiovascular journal of Africa 20110101

• Role of factor xa inhibitors in cancer-associated thrombosis: any new data?

  Advances in hematology 20110101

• Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.

  Journal of medical economics 20110101

• Emerging therapies for acute coronary syndromes.

  Frontiers in pharmacology 20110101

• The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.

  BMC musculoskeletal disorders 20110101

• Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

  BMJ (Clinical research ed.) 20110101

• Rivaroxaban, ticagrelor, and fidaxomicin.

  Journal of the American Pharmacists Association : JAPhA 20110101

• Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement.

  Thrombosis 20110101

• Venous thromboembolism: classification, risk factors, diagnosis, and management.

  ISRN hematology 20110101

• Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants.

  Thrombosis journal 20110101

• Anticoagulants and the propagation phase of thrombin generation.

  PloS one 20110101

• Gene-drug interaction in stroke.

  Stroke research and treatment 20110101

• Raft of rivaroxaban good news from the USA, implications for South African clinical practice.

  Cardiovascular journal of Africa 20110101

• Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.

  International journal of nanomedicine 20110101

• Cardiac arrest caused by multiple recurrent pulmonary embolism.

  Case reports in medicine 20110101

• Pharmacological basis and clinical evidence of dabigatran therapy.

  Journal of hematology & oncology 20110101

• The case for an elderly targeted stroke management.

  Frontiers in neurology 20110101

• Oral thromboprophylaxis following total hip or knee replacement: review and multicentre experience with dabigatran etexilate.

  The open orthopaedics journal 20110101

• Deep vein thrombosis: a clinical review.

  Journal of blood medicine 20110101

• Oral rivaroxaban for symptomatic venous thromboembolism.

  The New England journal of medicine 20101223

• Therapeutic potential of oral factor Xa inhibitors.

  The New England journal of medicine 20101223

• Engineered thrombin aims to take on heparin.

  Chemistry & biology 20101222

• Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments.

  Journal of the American College of Cardiology 20101214

• [Rivaroxaban at least as effective as marcumar in stroke prevention].

  MMW Fortschritte der Medizin 20101202

• [New oral anticoagulants: better than vitamin K antagonists?].

  Der Internist 20101201

• Assays for measuring rivaroxaban: their suitability and limitations.

  Therapeutic drug monitoring 20101201

• The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?

  Current opinion in anaesthesiology 20101201

• The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.

  British journal of haematology 20101201

• Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.

  Thrombosis and haemostasis 20101201

• New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.

  Clinics in chest medicine 20101201

• Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?

  Acta clinica Croatica 20101201

• Clinical pharmacology of direct and indirect factor Xa inhibitors.

  Drugs 20101112

• Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.

  Annals of the Royal College of Surgeons of England 20101101

• An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.

  Thrombosis and haemostasis 20101101

• Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

  European journal of clinical pharmacology 20101101

• Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

  Circulation. Cardiovascular quality and outcomes 20101101

• Blood transfusion and the anaesthetist: management of massive haemorrhage.

  Anaesthesia 20101101

• [Prophylaxis of thrombembolic diseases with rivaroxaban].

  Deutsche medizinische Wochenschrift (1946) 20101101

• Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.

  British journal of clinical pharmacology 20101101

• Korean guidelines for the prevention of venous thromboembolism.

  Journal of Korean medical science 20101101

• [Novel anticoagulants for stroke prevention in atrial fibrillation].

  Deutsche medizinische Wochenschrift (1946) 20101101

• [New oral anticoagulants from the perspective of trauma surgery].

  Der Unfallchirurg 20101101

• [Thromboembolism prophylaxis in trauma surgery: S3 guidelines and significance of the amendment for trauma surgeons].

  Der Unfallchirurg 20101101

• [Recommendations for the administration of conventional and new antithrombotic agents from the perspective of anesthesiology].

  Der Unfallchirurg 20101101

• [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

  Annales pharmaceutiques francaises 20101101

• [New study findings in cardiology. The best is the enemy of the good].

  Medizinische Monatsschrift fur Pharmazeuten 20101101

• New options for stroke prevention in atrial fibrillation.

  The American journal of managed care 20101101

• Rivaroxaban: a novel anticoagulant.

  Indian journal of medical sciences 20101101

• New antithrombotics for atrial fibrillation.

  Cardiovascular therapeutics 20101001

• Emerging antithrombotic agents: what does the intensivist need to know?

  Current opinion in critical care 20101001

• Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

  Thrombosis and haemostasis 20101001

• Low risk of thromboembolic complications after fast-track hip and knee arthroplasty.

  Acta orthopaedica 20101001

• Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.

  Anaesthesia 20101001

• Factor Xa inhibitors: next-generation antithrombotic agents.

  Journal of medicinal chemistry 20100909

• Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

  Journal of clinical pharmacology 20100901

• [Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].

  Zeitschrift fur Orthopadie und Unfallchirurgie 20100901

• New antithrombotic agents--insights from clinical trials.

  Nature reviews. Cardiology 20100901

• Novel oral anticoagulants: implications in the perioperative setting.

  Anesthesiology 20100901

• [Rivaroxaban and factor Xa inhibitors in clinical practice].

  Vnitrni lekarstvi 20100901

• Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.

  Journal of cardiovascular pharmacology 20100801

• Anticoagulation by factor Xa inhibitors.

  Journal of thrombosis and haemostasis : JTH 20100801

• Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.

  Thrombosis and haemostasis 20100801

• Treatment of thromboembolism in cancer patients.

  Expert opinion on pharmacotherapy 20100801

• Oral Xa inhibitors.

  Hematology/oncology clinics of North America 20100801

• [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801

• Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.

  Current opinion in cardiology 20100701

• New oral anticoagulant drugs in cardiovascular disease.

  Thrombosis and haemostasis 20100701

• Clot prevention--common questions about medications.

  Australian family physician 20100701

• [A new deal with new anticoagulants?].

  Journal des maladies vasculaires 20100601

• Old versus new anticoagulants: focus on pharmacology.

  Recent patents on cardiovascular drug discovery 20100601

• Anesthetic concerns for patients with coagulopathy.

  Current opinion in anaesthesiology 20100601

• Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.

  The Annals of pharmacotherapy 20100601

• Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.

  Anaesthesia 20100601

• Drug and dietary interactions of the new and emerging oral anticoagulants.

  International journal of clinical practice 20100601

• Novel oral anticoagulants. Part II: direct thrombin inhibitors.

  Expert review of hematology 20100601

• [New oral anticoagulants: prospects].

  La Revue du praticien 20100520

• Emerging anticoagulants for venous thromboembolism prevention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100515

• New anticoagulants for prevention and treatment of venous thromboembolism.

  Current vascular pharmacology 20100501

• Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.

  Archives of orthopaedic and trauma surgery 20100501

• New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100501

• Primary prevention of venous thromboembolism in medical and surgical oncology patients.

  British journal of cancer 20100413

• Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

  Thrombosis and haemostasis 20100401

• Facts and artefacts of coagulation assays for factor Xa inhibitors.

  Thrombosis and haemostasis 20100401

• Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?

  Lupus 20100401

• Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.

  Croatian medical journal 20100401

• VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.

  Thrombosis research 20100401

• Potential of new anticoagulants in patients with cancer.

  Thrombosis research 20100401

• Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors).

  Expert review of hematology 20100401

• Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

  Thrombosis and haemostasis 20100301

• DVT: a new era in anticoagulant therapy.

  Arteriosclerosis, thrombosis, and vascular biology 20100301

• Rivaroxaban: a new oral factor Xa inhibitor.

  Arteriosclerosis, thrombosis, and vascular biology 20100301

• Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events.

  The Lancet. Neurology 20100301

• Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

  American heart journal 20100301

• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.

  The Journal of bone and joint surgery. British volume 20100301

• Recent advances in the management of venous thromboembolism.

  The Korean journal of hematology 20100301

• New oral anticoagulants: a practical guide for clinicians.

  Journal of thrombosis and thrombolysis 20100201

• The ultimate anticoagulants?

  Cardiovascular journal of Africa 20100201

• [Update on new antithrombotic treatments].

  Revue medicale suisse 20100120

• The new oral anticoagulants.

  Blood 20100107

• Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.

  Current vascular pharmacology 20100101

• Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.

  Thrombosis and haemostasis 20100101

• The potential benefits of low-molecular-weight heparins in cancer patients.

  Journal of hematology & oncology 20100101

• [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].

  Zeitschrift fur Orthopadie und Unfallchirurgie 20100101

• Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban).

  Current topics in medicinal chemistry 20100101

• New oral anticoagulants in development: potential for improved safety profiles.

  Reviews in neurological diseases 20100101

• Forecasting drug utilization and expenditure in a metropolitan health region.

  BMC health services research 20100101

• New options with dabigatran etexilate in anticoagulant therapy.

  Vascular health and risk management 20100101

• New anticoagulants for the prevention of venous thromboembolism.

  Drug design, development and therapy 20100101

• Deep vein thrombosis and pulmonary embolism - Prevention, management, and anaesthetic considerations.

  Indian journal of anaesthesia 20100101

• Novel anticoagulant therapy: principle and practice.

  Methods in molecular biology (Clifton, N.J.) 20100101

• Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.

  Methods in molecular biology (Clifton, N.J.) 20100101

• [Anticoagulant therapy in cardiology: yesterday, today, tomorrow].

  Kardiologiia 20100101

• Prevention strategies for cardioembolic stroke: present and future perspectives.

  The open neurology journal 20100101

• Oral anticoagulants in pediatric cardiac practice: A systematic review of the literature.

  Annals of pediatric cardiology 20100101

• Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

  PharmacoEconomics 20100101

• Further issues with new oral anticoagulants.

  Current pharmaceutical design 20100101

• New anticoagulants for the prevention of thromboembolism.

  Current pharmaceutical design 20100101

• Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.

  Current pharmaceutical design 20100101

• Managing bleeding complications in patients treated with the old and the new anticoagulants.

  Current pharmaceutical design 20100101

• Post-operative thromboprophylaxis: new oral thrombin and factor X inhibitors and their place in clinical practice.

  F1000 medicine reports 20100101

• Effective single-drug approach is welcomed for deep-vein thrombosis treatment.

  Cardiovascular journal of Africa 20100101

• Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke.

  Cardiovascular journal of Africa 20100101

• Development of new anticoagulant highly honoured: Bayer's Xarelto recognised with 2010 international Prix Galien award.

  Cardiovascular journal of Africa 20100101

• Newer antithrombotic drugs.

  Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20100101

• Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.

  Thrombosis 20100101

• New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty.

  Thrombosis 20100101

• Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations.

  Journal of blood medicine 20100101

• Dabigatran or rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety.

  CADTH technology overviews 20100101

• Rivaroxaban in orthopedic surgery--a change of paradigm?

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20091201

• Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review.

  Internal and emergency medicine 20091201

• Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?

  Journal of thrombosis and haemostasis : JTH 20091201

• [New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].

  Der Anaesthesist 20091201

• Rivaroxaban, the first oral, direct factor Xa inhibitor.

  Expert opinion on pharmacotherapy 20091201

• Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?

  Discovery medicine 20091201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091201

• Heparin-induced thrombocytopaenia/thrombosis: a clinicopathologic review.

  East African medical journal 20091201

• Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?

  Thrombosis and haemostasis 20091101

• Thromboprophylaxis after multiple trauma: what treatment and for how long?

  Injury 20091101

• [Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].

  Journal des maladies vasculaires 20091101

• New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.

  ANZ journal of surgery 20091101

• New antithrombotic drugs: potential for use in oncology.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091010

• Underestimation of the effect of bleeding in clinical trials.

  Lancet (London, England) 20091003

• New anticoagulants and regional anesthesia.

  Current opinion in anaesthesiology 20091001

• Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.

  Drug and therapeutics bulletin 20091001

• Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

  Health technology assessment (Winchester, England) 20091001

• [Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].

  Revue medicale de Liege 20091001

• Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.

  Current opinion in hematology 20090901

• A logical approach to surgical thromboprophylaxis.

  Current opinion in hematology 20090901

• [Orthopedic patients with or without thrombophilia. Diagnostic, therapy and peri-operative strategies].

  Der Orthopade 20090901

• [New developments in antithrombotic care].

  Revue medicale de Bruxelles 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Rivaroxaban versus enoxaparin after total knee arthroplasty.

  Lancet (London, England) 20090829

• Rivaroxaban versus enoxaparin after total knee arthroplasty.

  Lancet (London, England) 20090829

• Rivaroxaban versus enoxaparin after total knee arthroplasty.

  Lancet (London, England) 20090829

• Rivaroxaban versus enoxaparin after total knee arthroplasty.

  Lancet (London, England) 20090829

• Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

  Journal of thrombosis and haemostasis : JTH 20090801

• Recent developments in the use of oral anticoagulants.

  Expert opinion on pharmacotherapy 20090801

• Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.

  Journal of cardiovascular medicine (Hagerstown, Md.) 20090801

• Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.

  Annals of surgery 20090801

• Factor Xa inhibitors--new anticoagulants for secondary haemostasis.

  Hamostaseologie 20090801

• [Patients with oral anticoagulation--bridging anticoagulation in the perioperative phase].

  Hamostaseologie 20090801

• Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.

  Prescrire international 20090801

• Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

  Lancet (London, England) 20090704

• Rivaroxaban in acute coronary syndromes: too soon to know?

  Lancet (London, England) 20090704

• New anticoagulants: focus on venous thromboembolism.

  Current vascular pharmacology 20090701

• Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.

  British journal of clinical pharmacology 20090701

• New anticoagulants for atrial fibrillation.

  Seminars in thrombosis and hemostasis 20090701

• [New agents for the prevention of venous thromboembolism].

  Der Internist 20090601

• Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.

  Expert review of cardiovascular therapy 20090601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090601

• 3-(3-Chloro-anilino)-1-(3,5-dimethyl-1H-pyrazol-1-yl)propan-1-one.

  Acta crystallographica. Section E, Structure reports online 20090601

• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.

  Lancet (London, England) 20090516

• The importance of VTE prevention after orthopaedic surgery.

  Lancet (London, England) 20090516

• Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.

  European journal of haematology 20090501

• Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.

  Drug metabolism and disposition: the biological fate of chemicals 20090501

• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.

  The Journal of bone and joint surgery. British volume 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor.

  P & T : a peer-reviewed journal for formulary management 20090501

• [The new oral anticoagulant in the Netherlands].

  Nederlands tijdschrift voor geneeskunde 20090418

• Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.

  Bioorganic & medicinal chemistry letters 20090415

• The direct factor Xa inhibitor rivaroxaban.

  The Medical journal of Australia 20090406

• Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.

  Expert opinion on pharmacotherapy 20090401

• [New anticoagulants].

  Deutsche medizinische Wochenschrift (1946) 20090401

• Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?

  Archives of cardiovascular diseases 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• [Venous thromboembolism prophylaxis in orthopaedics and traumatology].

  Vnitrni lekarstvi 20090301

• [Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].

  Vnitrni lekarstvi 20090301

• The novel anticoagulants: entering a new era.

  Swiss medical weekly 20090207

• [The new antithrombotics in 2009].

  Revue medicale suisse 20090204

• Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

  Pharmacotherapy 20090201

• New anticoagulants - towards the development of an 'ideal' anticoagulant.

  VASA. Zeitschrift fur Gefasskrankheiten 20090201

• Laboratory monitoring of anticoagulation: where do we stand?

  Seminars in thrombosis and hemostasis 20090201

• Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

  Clinical pharmacokinetics 20090101

• Multinational development of a questionnaire assessing patient satisfaction with anticoagulant treatment: the 'Perception of Anticoagulant Treatment Questionnaire' (PACT-Q).

  Health and quality of life outcomes 20090101

• In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.

  Orthopedics 20090101

• New oral anticoagulants: not quite there yet.

  Polskie Archiwum Medycyny Wewnetrznej 20090101

• Old and new anticoagulant agents for the prevention and treatment of patients with ischemic stroke.

  Cerebrovascular diseases (Basel, Switzerland) 20090101

• Use of anticoagulants in elderly patients: practical recommendations.

  Clinical interventions in aging 20090101

• Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.

  Cardiology in review 20090101

• Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

• Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.

  Vascular health and risk management 20090101

• The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

  Vascular health and risk management 20090101

• [Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

  Drugs 20090101

• [From old to new anticoagulants: the role of the biologist].

  Annales de biologie clinique 20090101

• New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?

  PharmacoEconomics 20090101

• A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

  PharmacoEconomics 20090101

• Prevention and treatment of thromboembolic events in medical patients and new anticoagulants.

  Acta clinica Belgica 20090101

• [Pharmacology of heparins and direct anticoagulants].

  Hamostaseologie 20081201

• [Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?].

  Annales francaises d'anesthesie et de reanimation 20081201

• [Rivaroxaban: clinical pharmacology].

  Annales francaises d'anesthesie et de reanimation 20081201

• [Perioperative venous thromboembolism prophylaxis: short review and recommendations].

  Annales francaises d'anesthesie et de reanimation 20081201

• [Rivaroxaban (Xarelto): efficacy and safety].

  Annales francaises d'anesthesie et de reanimation 20081201

• [Summary and perspectives. Rivaroxaban].

  Annales francaises d'anesthesie et de reanimation 20081201

• [Rivaroxaban: mode of action].

  Annales francaises d'anesthesie et de reanimation 20081201

• Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.

  Vascular health and risk management 20081201

• Rivaroxaban for thromboprophylaxis.

  The New England journal of medicine 20081113

• Rivaroxaban for thromboprophylaxis.

  The New England journal of medicine 20081113

• Rivaroxaban for thromboprophylaxis.

  The New England journal of medicine 20081113

• Rivaroxaban for thromboprophylaxis.

  The New England journal of medicine 20081113

• [Rivaroxaban. The first factor Xa inhibitor].

  Medizinische Monatsschrift fur Pharmazeuten 20081101

• [Thromboembolic disease in orthopedic surgery].

  Medicina clinica 20081101

• [Anaesthesia and thromboembolic disease].

  Medicina clinica 20081101

• [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].

  Medicina clinica 20081101

• Polyphosphate as a general procoagulant agent.

  Journal of thrombosis and haemostasis : JTH 20081001

• Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.

  British journal of haematology 20081001

• Differences in urinary prothrombin fragment 1 + 2 levels after total hip replacement in relation to venous thromboembolism and bleeding events.

  Journal of thrombosis and haemostasis : JTH 20081001

• Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.

  Current medical research and opinion 20081001

• [Anticoagulation in atrial fibrillation].

  Hamostaseologie 20081001

• [Prophylaxis of venous thromboembolism].

  Hamostaseologie 20081001

• Rivaroxaban: future in anticoagulation practice?

  Hematology (Amsterdam, Netherlands) 20081001

• More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.

  DukeMedicine healthnews 20081001

• [Always more amputations in Germany?].

  Deutsche medizinische Wochenschrift (1946) 20081001

• Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.

  Neurosurgery 20081001

• A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.

  Blood 20080915

• Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901

• Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.

  Thrombosis and haemostasis 20080901

• New developments in anticoagulation for atrial fibrillation.

  Current treatment options in cardiovascular medicine 20080901

• Rivaroxaban: an oral direct inhibitor of factor Xa.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080815

• Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

  Clinical orthopaedics and related research 20080801

• New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.

  Vascular health and risk management 20080801

• Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.

  Lancet (London, England) 20080705

• Selective factor Xa inhibition for thromboprophylaxis.

  Lancet (London, England) 20080705

• Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

  The New England journal of medicine 20080626

• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

  The New England journal of medicine 20080626

• New anticoagulants--the path from discovery to clinical practice.

  The New England journal of medicine 20080626

• Rivaroxaban, an oral direct factor Xa inhibitor.

  Expert opinion on investigational drugs 20080601

• [Hematology 2008].

  Deutsche medizinische Wochenschrift (1946) 20080601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080601

• Preventing venous thromboembolism through risk assessment approaches.

  British journal of nursing (Mark Allen Publishing) 20080601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080401

• Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

  Clinical orthopaedics and related research 20080301

• New anticoagulants for treatment of venous thromboembolism.

  Arteriosclerosis, thrombosis, and vascular biology 20080301

• Update on atrial fibrillation: part I.

  Clinical cardiology 20080201

• [New anticoagulants].

  Hamostaseologie 20080201

• Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

  Seminars in thrombosis and hemostasis 20080201

• The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update.

  Seminars in thrombosis and hemostasis 20080201

• Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

  Drug safety 20080101

• New oral anticoagulants in atrial fibrillation.

  European heart journal 20080101

• Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

  Clinical pharmacokinetics 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Pharmacological strategies for inhibition of thrombin activity.

  Current pharmaceutical design 20080101

• The top 4 advances in antithrombotic care in the last year.

  Thrombosis research 20080101

• Brave new world: the current and future use of novel anticoagulants.

  Thrombosis research 20080101

• Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty.

  ACP journal club 20080101

• Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in knee arthroplasty.

  ACP journal club 20080101

• Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

  Journal of autoimmune diseases 20080101

• New issues in oral anticoagulants.

  Hematology. American Society of Hematology. Education Program 20080101

• Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.

  Pathophysiology of haemostasis and thrombosis 20080101

• Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.

  Journal of clinical pharmacology 20071101

• Development of oral anticoagulants.

  British journal of clinical pharmacology 20070901

• Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.

  Hamostaseologie 20070901

• Beyond unfractionated heparin and warfarin: current and future advances.

  Circulation 20070731

• A replacement for warfarin: the search continues.

  Circulation 20070710

• Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

  Circulation 20070710

• Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.

  Journal of thrombosis and haemostasis : JTH 20070701

• Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.

  Seminars in thrombosis and hemostasis 20070701

• Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.

  Arteriosclerosis, thrombosis, and vascular biology 20070601

• Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.

  Thrombosis and haemostasis 20070601

• Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20070601

• Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.

  British journal of clinical pharmacology 20070401

• Investigational treatments of venous thromboembolism.

  Expert opinion on investigational drugs 20070401

• In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.

  Journal of thrombosis and haemostasis : JTH 20070401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.

  Thrombosis and haemostasis 20070301

• Rivaroxaban.

  Drugs of today (Barcelona, Spain : 1998) 20070301

• [New antitoagulants].

  Annales pharmaceutiques francaises 20070301

• Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.

  Current opinion in investigational drugs (London, England : 2000) 20070301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070301

• Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.

  Journal of clinical pharmacology 20070201

• Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.

  Thrombosis research 20070101

• Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.

  Annals of medicine 20070101

• Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy.

  Thrombosis journal 20070101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

  Circulation 20061128

• The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.

  Circulation 20061128

• Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.

  Journal of clinical pharmacology 20060901

• Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.

  Expert opinion on investigational drugs 20060801

• Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

  Journal of clinical pharmacology 20060501

• [Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches].

  Hamostaseologie 20060501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060401

• New oral anticoagulants show promise.

  JAMA 20060215

• Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.

  Journal of thrombosis and haemostasis : JTH 20060101

• Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

  European journal of clinical pharmacology 20051201

• BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.

  Journal of thrombosis and haemostasis : JTH 20051101

• Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

  Clinical pharmacology and therapeutics 20051001

• Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.

  Journal of medicinal chemistry 20050922

• Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.

  Xenobiotica; the fate of foreign compounds in biological systems 20050901

• New antithrombotics in the prevention of thromboembolic disease.

  European journal of internal medicine 20050801

• In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.

  Journal of thrombosis and haemostasis : JTH 20050301